ClinicalTrials.gg
CompletedNCT02733185TACT2Updated Mar 30, 2025Results posted

Trial to Assess Chelation Therapy 2

A Phase 3 interventional study of disodium EDTA and Oral Multi Vitamins/Minerals (OMVM) in Diabetes and Myocardial Infarction, sponsored by Mt. Sinai Medical Center, Miami. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Mt. Sinai Medical Center, Miami · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,023 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Enrollment
175th of 2,502
1,000 · median 82
Started
2016
with 124 others
Phase 3
306 of 3,023
4 open now
Registered
1,895th of 3,023
by date

Among the 3,023 studies in Diabetes Mellitus with a site in United States, this one is the 175th largest by enrollment of the 2,502 interventional ones that give a count, is one of 125 that started in 2016, is one of 306 in phase 3, and was the 1,895th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,023 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,023 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

Trial to Assess Chelation Therapy 2 (TACT2) is a randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction (MI).

Read the detailed description

The primary objective of TACT2, therefore, is to determine if the chelation-based strategy increases the time to the first occurrence of any of the components of the TACT2 primary endpoint: all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina compared to the placebo chelation strategy.

TACT2 is a 2x2 factorial trial testing 40-weekly edetate disodium-based chelation infusions and twice daily high-dose oral multivitamins and multiminerals (OMVM) in a placebo-controlled design.

TACT2 is being carried out to replicate the findings of TACT1, which found a striking reduction of recurrent cardiovascular events in post-MI diabetic patients receiving edetate disodium-based chelation therapy.

03

Conditions studied

  • Diabetes
  • Myocardial Infarction

Keywords

  • chelation
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: ≥ 50 years
  2. History of diabetes, defined as medical record evidence or patient report of currently using insulin or oral hypoglycemic agents, or with a history of fasting blood glucose measurement of 126 mg/dL or higher, or a history of of 6.5% or higher.
  3. History of myocardial infarction based on the Universal Definition of MI.

    1. When information about the MI hospitalization is available, all MI types except Type 2 qualify for study entry.
    2. When information about the MI hospitalization is not available, a wall motion abnormality on imaging or a perfusion defect on scan that corresponds to a coronary distribution, whether or not accompanied by pathological Q waves in the appropriate distribution, will qualify the patient for study entry. This criterion requires a call to the CCC for case review.

Exclusion criteria

Exclusion Criteria:

  1. Baseline serum creatinine >2.0 mg/dL.
  2. >11%.
  3. Myocardial infarction within 6 weeks of randomization.
  4. History of allergic reactions to EDTA or any other components of the chelation solution, including heparin. Site personnel are to call the CCC to discuss heparin allergy.
  5. Coronary or peripheral arterial revascularization procedure performed within the last 6 months.
  6. Planned revascularization procedure in the 6 months following enrollment.
  7. Heart failure hospitalization within 6 months prior to enrollment or in clinical heart failure at the time of proposed enrollment (such as Class 3 dyspnea + rales >basilar, and additional signs of fluid overload). Such patients may be treated with diuretics and enrolled when stable.
  8. Poor or no venous access in the upper extremities.
  9. a. Prior intravenous chelation therapy consisting of > 1 infusion within 5 years; if only 1 infusion took place, patient cannot be enrolled for at least 12 months after said infusion.

    b. Oral chelation therapy with an approved oral chelating agent within 2 years.

  10. Prior participation in TACT.
  11. Baseline count \<100,000.
  12. History of cigarette smoking within the last 3 months.
  13. or AST > 2.0 times the .
  14. Wilson's disease, hemochromatosis, or parathyroid disease.
  15. Any medical condition including a current diagnosis of cancer (except non-melanoma skin cancer) that will limit patient survival over the duration of the trial.
  16. Any factor that suggests that the potential participant will not be able to adhere to the protocol.
  17. Women of including those with plans for in vitro fertilization or other reproductive technology.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,000 participants (actual)

Study arms

  • Active comparator
    Active/Active

    Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)

    Drug: disodium EDTA · Dietary Supplement: Oral Multi Vitamins/Minerals (OMVM)

  • Active comparator
    Active/Placebo

    Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)

    Drug: disodium EDTA

  • Active comparator
    Placebo/ Active

    Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)

    Dietary Supplement: Oral Multi Vitamins/Minerals (OMVM) · Drug: Placebo disodium EDTA

  • Placebo comparator
    Placebo/Placebo

    Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)

    Drug: Placebo disodium EDTA · Dietary Supplement: Placebo Oral Multi Vitamins/Minerals (OMVM)

Interventions

  • DrugEdetic AcidStudies of Edetic AcidEdetic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IV Disodium Ethylene diamine tetra acetic acid in 500 cc

    Also known as: EDTA

  • Dietary supplementOral Multi Vitamins/Minerals (OMVM)

    6 tablets of Multi-vitamin/Multimineral daily

  • DrugPlacebo disodium EDTA

    IV Placebo comparator- 500 normal saline

  • Dietary supplementPlacebo Oral Multi Vitamins/Minerals (OMVM)

    6 tablets of a placebo Multi-vitamin/Multimineral daily

06

What researchers measure

Primary outcomes

  1. Primary Composite Outcome

    Time to first event: myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or death from any cause

    Time frame: 48 month follow-up (median)

Secondary outcomes

  1. Secondary Composite Outcome

    Time to first event: myocardial infarction, stroke, or death from cardiovascular causes

    Time frame: 48 month follow-up (median)

  2. Secondary Outcome

    Time to All-Cause mortality

    Time frame: All-Cause Mortality was assessed through study completion, up to 48 months (median)

07

Results

Posted Oct 1, 2024
Limitations and caveats
Primary analyses were restricted to a modified intention-to-treat. Treatment adherence was imperfect. 12% of participants were lost to follow-up or withdrew consent.

Participant flow

A total of 1,000 patients were enrolled at 88 clinical centers from United States (83) and Canada (5). The first patient was enrolled on October 18, 2017 and the last patient on December 31, 2020. Each patient was randomly assigned to 1 of the 4 treatment groups.

Participant flow — Overall Study
MilestoneActive/ActiveActive/PlaceboPlacebo/ ActivePlacebo/Placebo
Started250249250251
Completed175187182176
Not completed75626875
Withdrew: Withdrawal by subject12101721
Withdrew: Death46343543
Withdrew: Lost to follow-up17181611

Outcome measures

PrimaryPrimary Composite Outcome

Time to first event: myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or death from any cause

Time frame:
48 month follow-up (median)
Reported as:
Count of participants · Participants
Primary Composite Outcome
ParticipantsActive/ActiveActive/PlaceboPlacebo/ ActivePlacebo/Placebo
Primary Composite Outcome85899086
SecondarySecondary Composite Outcome

Time to first event: myocardial infarction, stroke, or death from cardiovascular causes

Time frame:
48 month follow-up (median)
Reported as:
Count of participants · Participants
Secondary Composite Outcome
ParticipantsActive/ActiveActive/PlaceboPlacebo/ ActivePlacebo/Placebo
Secondary Composite Outcome50405541
SecondarySecondary Outcome

Time to All-Cause mortality

Time frame:
All-Cause Mortality was assessed through study completion, up to 48 months (median)
Reported as:
Count of participants · Participants
Secondary Outcome
ParticipantsActive/ActiveActive/PlaceboPlacebo/ ActivePlacebo/Placebo
Secondary Outcome50364049

Adverse events

Collected over All adverse events were collected from randomization until 30 days after their final infusion, approximately 13 months All-Cause Mortality was assessed through study completion, up to 48 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active EDTA/Active Vitamins50/250 (20%)41/250 (16.4%)0/250 (0%)
Active EDTA /Placebo Vitamins36/249 (14.5%)40/249 (16.1%)0/249 (0%)
Placebo EDTA/ Active Vitamins40/250 (16%)40/250 (16%)0/250 (0%)
Placebo EDTA/Placebo Vitamins49/251 (19.5%)40/251 (15.9%)0/251 (0%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventActive EDTA/Active VitaminsActive EDTA /Placebo VitaminsPlacebo EDTA/ Active VitaminsPlacebo EDTA/Placebo Vitamins
Infections and infestationsInfections and infestations10/2508/24917/25014/251
Cardiac disordersCardiac disorders7/25015/24911/25015/251
Renal and Urinary DisordersRenal and urinary disorders6/2503/2492/2503/251
Nervous System DisordersNervous system disorders6/2500/2493/2506/251
Gastrointestinal DisordersGastrointestinal disorders3/2505/2492/2501/251
Metabolism and nutrition disordersMetabolism and nutrition disorders4/2505/2491/2500/251
General disorders and administration site conditionsGeneral disorders4/2504/2492/2501/251
Vascular disordersVascular disorders2/2502/2491/2504/251
Neoplasms benign, malignant and unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/2503/2492/2501/251
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders2/2502/2493/2502/251

Baseline characteristics

Age, Continuous
Age, Continuous(years)Active/ActiveActive/PlaceboPlacebo/ ActivePlacebo/PlaceboTotal
Median66 (59 to 72)67 (61 to 72)67 (61 to 72)67 (61 to 72)67 (60 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)Active/ActiveActive/PlaceboPlacebo/ ActivePlacebo/PlaceboTotal
Female61797555270
Male189170175196730
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active/ActiveActive/PlaceboPlacebo/ ActivePlacebo/PlaceboTotal
Hispanic or Latino46535346198
Not Hispanic or Latino200191197201789
Unknown or Not Reported450413
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active/ActiveActive/PlaceboPlacebo/ ActivePlacebo/PlaceboTotal
American Indian or Alaska Native01315
Asian1511121654
Native Hawaiian or Other Pacific Islander535518
Black or African American34221926101
White186194204194778
More than one race13116
Unknown or Not Reported9156838
Region of Enrollment
Region of Enrollment(participants)Active/ActiveActive/PlaceboPlacebo/ ActivePlacebo/PlaceboTotal
North America2502492502511000
Type II Diabetes
Type II Diabetes(Participants)Active/ActiveActive/PlaceboPlacebo/ ActivePlacebo/PlaceboTotal
Count of participants239242235244960
Time from diabetes diagnosis to randomization
Time from diabetes diagnosis to randomization(years)Active/ActiveActive/PlaceboPlacebo/ ActivePlacebo/PlaceboTotal
Median13 (7 to 20)15 (8 to 21)15 (7 to 24)14 (7 to 21)14 (7 to 22)
Time from qualifying MI to randomization
Time from qualifying MI to randomization(years)Active/ActiveActive/PlaceboPlacebo/ ActivePlacebo/PlaceboTotal
Median5 (2 to 9)5 (2 to 10)5 (2 to 11)5 (2 to 10)5 (2 to 10)

10 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Mount Sinai Medical Center
    Miami Beach, Florida 33132, United States
09

References and documents

Publications

  • Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; TACT Investigators. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013 Mar 27;309(12):1241-50. doi: 10.1001/jama.2013.2107. PubMed 23532240 ↗
  • Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, Lee KL. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):15-24. doi: 10.1161/CIRCOUTCOMES.113.000663. Epub 2013 Nov 19. PubMed 24254885 ↗
  • Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Terry Chappell L, Lindblad L, Lewis EF, Drisko J, Lee KL. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. Am Heart J. 2014 Jul;168(1):37-44.e5. doi: 10.1016/j.ahj.2014.02.012. Epub 2014 Apr 2. PubMed 24952858 ↗
  • Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J. 2012 Jan;163(1):7-12. doi: 10.1016/j.ahj.2011.10.002. PubMed 22172430 ↗
  • Lamas GA, Anstrom KJ, Navas-Acien A, Boineau R, Kim H, Rosenberg Y, Stylianou M, Jones TLZ, Joubert BR, Santella RM, Escolar E, Aude YW, Fonseca V, Elliott T, Lewis EF, Farkouh ME, Nathan DM, Mon AC, Gosnell L, Newman JD, Mark DB; TACT2 Investigators. The trial to assess chelation therapy 2 (TACT2): Rationale and design. Am Heart J. 2022 Oct;252:1-11. doi: 10.1016/j.ahj.2022.05.013. Epub 2022 May 19. PubMed 35598636 ↗
  • Navas-Acien A, Santella RM, Joubert BR, Huang Z, Lokhnygina Y, Ujueta F, Gurvich I, LoIacono NJ, Ravalli F, Ward CD, Jarrett JM, Salazar AL, Boineau R, Jones TLZ, Mark DB, Newman JD, Nathan DM, Anstrom KJ, Lamas GA. Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2). Am Heart J. 2024 Jul;273:72-82. doi: 10.1016/j.ahj.2024.04.005. Epub 2024 Apr 15. PubMed 38621575 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Jun 2023, 80 months.

Results were first posted in Oct 2024, 1 year 3 months after primary completion.

Of 63 non-industry phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 79. This study's 80 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2016
First posted
Apr 11, 2016
StartActual
Oct 1, 2016
Primary completionActual
Jun 30, 2023
CompletionActual
Jun 30, 2023
Results first posted
Oct 1, 2024
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02733185
Lead sponsor
Mt. Sinai Medical Center, Miami
Responsible party
Gervasio Lamas, MD (TACT2 Study Chair, Mt. Sinai Medical Center, Miami) — Principal investigator
First posted
Apr 11, 2016
Start date
Oct 1, 2016
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Results posted
Oct 1, 2024
Last update
Mar 30, 2025

Study contacts

Gervasio A Lamas, MD
study chair · Mount Sinai Medical Center of Florida
Kevin J Anstrom, PhD
principal investigator · University of North Carolina, Chapel Hill
Daniel B Mark, MD
principal investigator · Duke University (Duke Clinical Research Institute)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edetic Acid

Start the discussion